Evaluating Pharmaceuticals for Health Policy and Reimbursement

ISBN-13: 9780727917843 / Angielski / Miękka / 2004 / 280 str.

Nick Freemantle; Suzanne Hill; Nick Freemantle

Opis

Based on an international programme backed by WHO on the evaluation of pharmaceuticals, this book will look at models used in different countries and will discuss the issues surrounding this important aspect of health care: the involvement of different stakeholders, the economic and epidermiological aspects, the tensions between licensing and valuation. The authors believe the book would fill a gap between publications on trial analyses, meta analyses and guidelines, and the decision making processes of organisations such as NICE, and at the local level HMOs or health trusts. Chapters will be written by international experts involved in the WHO study.

Spis treści

Introduction.

Development of marketing authorisation procedures for pharmaceuticals.

Interpreting clinical evidence.

International pharmaceutical policy – health creation or wealth creation?.

The development of fourth hurdle policies around the world.

Economic modelling in drug reimbursement.

Priority–setting in health care: matching decision criteria with policy objectives.

The tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral.

sclerosis.

Relationship between stakeholders: managing the war of the words.

Medicines and the media: good information or misleading hype?.

How to promote quality use of cost–effective medicines.

Making it happen and making it sustainable.

Pricing of pharmaceuticals.

Evaluating pharmaceuticals for health policy in low and middle income country settings

Blurb

The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders. Chapters include Development of marketing authorisation procedures for pharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealth creation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteria with policy objectives Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war of words Medicine and the media: good information or misleading hype? How to promote quality use of cost–effective medicines Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middle income country settings. Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.